These exorbitant costs have made it extremely challenging to be able to continue to provide drug coverage to everyone who wants these drugs but does not have an FDA-approved medical or indication for these drugs, the company stated
It is in a class of drugs known as glucagon-like peptide 1 (GLP-1) agonists
Research suggests Mounjaro supports up to 26% weight loss after two years, about 10% more than another well-known weight-loss injection, Wegovy
After the run-in phase concluded, participants were randomly assigned to receive weekly subcutaneous semaglutide 2.4 mg (n = 134) or matching placebo (n = 67) for 68 weeks
Commonly reported side effects may include: Mild to moderate nausea Occasional vomiting or constipation Fatigue or headache in the early stages Appetite suppression, which is intended but can be dramatic for some users These effects are typically temporary and tend to subside as your body adjusts to the medication
Without specific combination data, we are operating in the territory of informed speculation rather than proven science